trending Market Intelligence /marketintelligence/en/news-insights/trending/apm4hxboiiqwleg0imtjgg2 content esgSubNav
In This List

BioTime director to step down

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


BioTime director to step down

BioTime Inc. said David Schlachet will step down from the company's board of directors and will not seek reelection at the company's 2018 annual meeting.

Schlachet's decision to step down was due to the logistics of being a director of the company while living in Israel. He will remain a director of Cell Cure Neurosciences Ltd., an Israel-based unit of BioTime.

The Alameda, Calif.-based company develops therapies for degenerative diseases.